Discussion  by unknown
were bronchoscopy or mediastinoscopy. Only 3 thoracoto-
mies were performed for what was ultimately deemed a be-
nign process. Participation in our clinic, with early
involvement of a thoracic surgeon, may have prevented un-
necessary procedures. Whereas 5% (20/414) of patients in
our series underwent a diagnostic procedure, the Interna-
tional Early Lung Cancer Action Program Investigators
reported nearly double the rate of diagnostic procedures—
9.4% (535/5646 patients with nodules).3
We were able to identify 10 patients with primary lung
cancer. Unfortunately, only 5 patients underwent curative re-
section. Early detection and frequent follow-up did not lead to
curative resection in the other 5 patients. In fact, 3 of the 5 pa-
tients who underwent curative resection required more than 2
years of follow-up before a clinical decision was made to per-
form a procedure for tissue diagnosis. The need for prolonged
follow-up was not due to change in the initial index lesion,
but to the development of new subcentimeter lesions, with
subsequent recommendations for continued follow-up.
The management and follow-up of patients with asy-
mptomatic pulmonary nodules remains an important and
challenging clinical problem. Although a number of profes-
sional societies provide recommendations to guide the care
of these patients, our experience with this group of patients
has not been straightforward. We were not able to centralize
the care of these patients at our institution, and close to half
of patients enrolled in our clinic did not complete 2 years of
follow-up at our center. Well over 1000 CT scans were
performed at our center in a cohort of 414 patients. Whereas
a diagnosis of primary lung cancer was made in 10 patients,
only 5 of these patients could be definitively treated with
surgery. At the time of this report, our formal clinic for
the evaluation and follow-up of patients with indeterminate
nodules has been disbanded owing to cutbacks in advanced
nurse practitioner personnel. We believe that further
prospective investigation is required to evaluate the optimal
treatment strategy for patients with indeterminate pulmo-
nary nodules and to determine the long-term benefits of
early detection.
We are grateful for the efforts of Dr Joel Cooper for the design
and inception of this clinic.
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Dr Joel D. Cooper (Philadelphia, Pa). I think you have proba-
bly disclosed conflict, which I was going to disclose, having been
involved in setting this up. I have no financial conflict. Ego is an-
other matter. [Laughter.]
Dr Veeramachaneni, it was a very good presentation, providing
a lot of very useful information. Perhaps I can summarize, as you
did, and add a little bit more.
Why does a surgeon want to get involved with ditzels, with little
nodules? As you pointed out, it certainly is a way of alleviating anx-
iety on the part of the patient and providing a service to the patient
and the primary physician, both of whom have received letters from
the radiologist saying, ‘‘You have a nodule. It could be lung cancer.
You should be followed up.’’ And who better to follow it up than
a surgeon, ideally a conservative surgeon, who is in the best posi-
tion to make a judgment as to what should be watched and what
should be excised? By the way, I think it does promulgate the inter-
est of thoracic surgeons in all things relating to lung cancer. I have
often been quoted as saying nothing is too small, in my opinion, for
a thoracic surgeon to be involved in.
I think it also fosters research into the early diagnosis: how to
tell which nodules are cancer or not. It not only maintains the ra-
diologic skills of the thoracic surgeons, but also encourages other
investigators to use this as a population base to figure out some
tag, some marker, some immunologic way of determining if a nod-
ule is malignant. Here you have a database, a group of patients
who are being followed up. I think that is another potential envi-
ronment.
I think it supports the minimally invasive treatment of early can-
cers, whether by ablative techniques or excisional techniques.
Again, I think it is not bad for the thoracic surgeon to be involved.
We started a clinic in Philadelphia. We talked to the HMO that
did not send their patients to our institution for CT scans. I said, ‘‘I
will not take the responsibility of following the patients and saving
you a lot of money and unnecessary surgery unless you agree to al-
low us out of network to do the CT scans,’’ and they said yes.
My final question concerns the loss of follow-up of patients.
Have you any idea as to whether it was because of the patient or
because of insurance issues, and do you have any follow-up on
those patients to know what the ultimate outcome was?
Dr Veeramachaneni. We lost 45% of our patients to follow-up,
and we were not able to contact all of them individually to deter-
mine why they did not follow up. All that we do have is a clinic
note that indicates that they were scheduled for follow-up and
they did not show up. A small subset of patients showed up for their
first clinic visit where the surgeon as well as the nurse practitioner
evaluated them. They were subsequently scheduled for follow-up.
About 20-odd patients in that group failed to show up for their first
follow-up. Those patients we have contacted. Approximately half
of them chose to continue follow-up with their referring physician
and the other half just chose to discontinue follow-up entirely. I do
not have a good sense of whether it was an insurance or financial-
driven thing, but given the large catchment area of WashingtonCardiovascular Surgery c Volume 137, Number 1 33
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sible.
Dr Cooper. I noticed that you had a very low incidence in the
use of PET scans, which I greatly applaud. I think their value is un-
certain for the 3-, 4-, 5-, and 6-mm nodule. The standard seems to
be that everybody gets a PET scan, and if they have a positive one,
they are told they have cancer. I certainly think that your limited use
of PET scan saved a lot of money for the system. Do you have any
comment as to what you believe the importance of PET scan is in
monitoring these patients?
DrVeeramachaneni. For this presentation, I did not actually in-
clude that information, but we had 42 patients out of the entire
cohort, or approximately 10%, who underwent PET imaging. It
suggested malignancy in 8 patients, but its accuracy was not
100%, because most of these lesions were in the 1-cm or perhaps
even smaller category.
Dr Cooper. Actually, we have only gotten started. We are fol-
lowing up about 130 patients. Six people came in with lung cancers
that were pretty obvious. It is surprising how many patients are out
there who have been followed up for lesions that even the conser-
vative individual would not normally follow. Maybe that is a sec-
ondary benefit.
My last question is this: You mentioned 2 patients who either
had widespread metastases or N2 disease when they were finally
discovered to have cancer. That is somewhat different from Claudia
Henschke’s experience. I know she has been subject to a lot of crit-
icism, but what she did demonstrate is that careful follow-up using
different types of tools for early nodules can lead to a resection of
those that are cancer, an extremely high cure rate, and a very low
incidence of unnecessary operative interventions. Have you any
messages for us on how to avoid following up patients and subse-
quently finding out that they have N2 or widespread disease? Do
you think in retrospect there is anything different that you would
have done?
DrVeeramachaneni. In 1 of those 2 patients the nodule in ques-
tion was in the setting of an apical scar. The patient was followed up
for a number of years, and there was some controversy as to
whether there was any radiographic change. In fact, this case was
actually presented at a multidisciplinary conference and the deci-
sion was made to offer the patient just another follow-up imaging
study in a 6-month interval. In the meantime, however, bone metas-
tasis developed. In the other patient, who presented with T1 N2 dis-
ease, the PET scan was also negative. I apologize that we do not
have standardized uptake value measurements of that patient be-
cause none were reported at that time, but micrometastatic disease
was noted at the time of thoracotomy.
Dr Cooper. Thank you very much, Dr Veeramachaneni. It was
a great paper.
DrRossM. Bremner (Phoenix, Ariz). I think one of the benefits
of having a clinic like this is to allow for easy referral for physicians
who do not know what to do with a pulmonary nodule. It may be
very obvious to us that it is a lung cancer. To allow that ease is
a great benefit of having such a clinic.
I have two quick questions. Do you have any information on the
cost-efficacy per patient who ended up being treated for cancer for
those 1000-plus scans that you did? Second, how did you address
the malpractice issues involved with this, the patients who do not
get followed up and then the patients whom you stop following34 The Journal of Thoracic and Cardiovascular Surgup after 2 years, who may have an indolent cancer or bronchioloal-
veolar carcinoma lesion.
Dr Veeramachaneni. I cannot comment on cost analysis. I do
not know the exact data as to how much revenue was generated
or the cost. That is somewhat of a soft number, as I have discovered
in terms of trying to figure out the exact cost of anything.
As to your second question, at the time that each patient is seen
in clinic, we recommend follow-up and we also schedule their fol-
low-up for their next visit. In addition, we inform the referring pri-
mary care physician of the need for follow-up and what our findings
were in the form of a letter. However, we have not tried to track
down those patients who do not show up subsequently.
Dr Scott J. Swanson (New York, NY). I enjoyed this. I think it is
a great addition to what we do as thoracic surgeons.
It seems to me you may want to rethink the 2-year strategy, since
over half of your patients presented after 2 years. What is your cur-
rent recommendation about how long to follow up patients? Did
you try to recontact the people that you dismissed after 2 years to
see how they are doing?
Dr Veeramachaneni. I completely agree with you that the
2-year benchmark was established in an era before high-resolution
CT scans and finding patients with these small nodules. Just as the
ELCAP trial demonstrated, we might be diagnosing these patients
at an earlier stage of cancer, but it is still a matter of debate as to
whether we are accomplishing improved morbidity or mortality
by acting on these data. Once we have identified patients with
a nodule, I think we are somewhat obligated to continue to counsel
these patients and follow them. We do not have a specific end
point.
As to the question of what do we do about the patients who were
dismissed from our clinic, all of these patients did have radio-
graphic stability and they did not have new nodules that would
have mandated further testing. If these individuals are considered
at high risk, their physicians might want to enroll them in a screen-
ing trial. However, right now I do not think there are any data to
support enrolling high-risk patients routinely into screening pro-
grams outside of a clinical trial.
Dr Frank C. Detterbeck (New Haven, Conn). The spectrum of
disease that we are seeing is changing dramatically. I recently did
a review of this. Tumor doubling time for normal, routine-care–
detected patients is 136 days on average, and in CT screening stud-
ies it is 485 days, dramatically different. That is why the whole
2-year mark is changing. It is clear that we are seeing indolent tu-
mors in a different spectrum of disease.
My question is really something to work on. I think that you
would be in an ideal situation to look at patients who were discov-
ered as part of a CT screening trial and those patients who happened
to be walking down the street within 100 yards of an emergency
room and somehow ended up with a scan and see if those are similar
populations. I suspect they are, but it would be very useful.
Dr Veeramachaneni. Thank you.
Dr Walter Klepetko (Vienna, Austria). How many of your
patients had a history of any other malignant disease? Did you ex-
clude those patients from such a study? Would it have any impact
on your follow-up strategy?
Dr Veeramachaneni. We did not exclude any patients who
were referred to our clinic. The 2 patients who received a diagnosis
of metastatic lesions in fact had a known history of nonlungery c January 2009
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colorectal cancer. In terms of clinical management and follow-up of
those nodules, it was left to the discretion of the surgeon evaluating
that patient whether it should be 6-month interval follow-up or 1-
year follow-up.
Dr Klepetko. My second question concerns your judgment of
changes in the size of the nodules. Was it done with the naked
eye of the radiologist or did you apply volumetric assessment?
Dr Veeramachaneni. I do not know the specific technique used
by our radiologists, but from my recent exposure to our radiolo-
gists, I do not believe they use an automated volumetric assessment.
They rely on the measurements that they routinely take. I should
stress that it is the same group of radiologists, the same CT scanner,
and, no doubt, the same technique.
Dr Cerfolio. How many people in the audience are using volu-
metric measurements for these ditzelomas with thin-cut CTs as op-
posed to just linear?
[A show of hands.]
Dr Cerfolio. That is what we have gone to at the University of
Alabama at Birmingham. I think that is a more accurate way. If they
have only one nodule, you can get them in and they get a thin slice,
they get less radiation, and they do not need intravenous contrast.
DrKlepetko. It is extremely helpful and provides very objective
data.
Dr Cerfolio. And it is more accurate.
Dr John R. Benfield (Los Angeles, Calif). A number of years
ago I reviewed a paper that was subsequently published in the An-
nals of Thoracic Surgery, which indicated that there is perhaps little
need, if any, for surgeons to follow up their patients postoperativelyThe Journal of Thoracic andlong term. I wrote an invited, or perhaps not so invited, commentary
speaking against that and in favor of surgeons following up their
patients. What is your posture toward following up patients postop-
eratively long term? Do you agree or disagree with the thesis that
long-term postoperative follow-up can simply be relegated to pri-
mary physicians or referring physicians?
Dr Veeramachaneni. I think as surgical oncologists and tho-
racic oncologists, we have an obligation to continue to follow up
these patients, and that is certainly the practice at Washington Uni-
versity.
Dr Erino Angelo Rendina (Rome, Italy). My question echoes
that of Dr Benfield. As a matter of fact, I think your paper is of ex-
treme interest from a speculative point of view. However, from the
standpoint of manpower, is it really indispensable that thoracic sur-
geons be involved in such a clinic, considering that in the time span
of 2 years, only 5 patients were operated on out of more than 400?
Dr Veeramachaneni. In the interest of full disclosure, I should
state that this clinic is formally disbanded owing to lack of nurse
practitioner personnel. This happened within the past year, but
these patients continue to be seen in the regular clinic. The way
the clinic was designed, a nurse practitioner who was following
up these solitary pulmonary nodule patients would show up at
the same time as the regular clinic. These patients would be sched-
uled at the same time as the regular clinic, but most of the patient
education follow-up would be done by the nurse practitioner. The
surgeon would be able to come in and say hello or provide
additional counseling, but the whole idea was to unburden the sur-
geon from routine follow-up while at the same time providing high-
quality care.Cardiovascular Surgery c Volume 137, Number 1 35
